571189-49-6CN1CCN(c2ccc(N)nc2)CC1QDMPMBFLXOWHRY-UHFFFAOYSA-N571189-49-6DTXSID80624889CHEMBL4535536Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H301 (33.3%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P351+P338, P305+P354+P338, P316, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P363, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 6 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Beschreibung5-(4-Methylpiperazin-1-yl)pyridin-2-amine is a pharmaceutical intermediate compound that can be used to prepare trilaciclib. Trilaciclib is the first intravenous CDK4/6 inhibitor approved by the FDA for reducing the risk of bone marrow suppression (i.e. decreased red blood cells, white blood cells, and platelets) in adult patients with small cell lung cancer (SCLC) caused by specific chemotherapy drugs.
Verwenden5-(4-Methylpiperazin-1-yl)pyridin-2-amine can be used for chemical mechanical planarization for tungsten-containing substrates.
Wird geladen…
Wird geladen…
Wird geladen…